The strategies to overcome resistance to ALK inhibitor in lung cancer.
Project/Area Number |
25462193
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Respiratory surgery
|
Research Institution | Chiba Cancer Center (Research Institute) |
Principal Investigator |
Yokoi Sana 千葉県がんセンター(研究所), がんゲノムセンター, 部長 (30372452)
|
Co-Investigator(Kenkyū-buntansha) |
Iizasa Toshihiko 千葉県がんセンター, 呼吸器外科, 部長 (10272303)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 肺癌 |
Outline of Final Research Achievements |
Anaplastic lymphoma kinase (ALK) which is one of the receptor tyrosine kinase is activated by chromosomal translocation and causes lung cancer (ALK lung cancer). ALK inhibitor shows remarkable effect for ALK lung cancer. However, ALK lung cancer becomes tolerance to ALK inhibitor in short time. To find a new therapeutic target for ALK lung cancer, the genomic abnormality was analyzed. As a result, we found a putative candidate gene which is decreased expression in ALK lung cancer by genomic deletion or DNA methylation in promoter region. A forced expression of this gene leads to the growth retardation in lung cancer cell line with ALK translocation.
|
Report
(3 results)
Research Products
(13 results)
-
[Journal Article] High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.2013
Author(s)
Itakura M, Terashima Y, Shingyoji M, Yokoi S, Ohira M, Kageyama H, Matui Y, Yoshida Y, Ashinuma H, Moriya Y, Tamura H, Harigaya K, Matushima K, Iizasa T, Nakagawara A, Kimura H.
-
Journal Title
Br J Cancer.
Volume: 109
Pages: 1100-1108
Related Report
Peer Reviewed
-
[Journal Article] Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.2013
Author(s)
Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K, Iizasa T.
-
Journal Title
Lung Cancer
Volume: 82
Pages: 282-287
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-